Cytek Biosciences reaffirms its 2024 revenue guidance, expecting full year 2024 revenue in the range of $203 million to $213 million, representing growth of 5% to 10% over full year 2023, assuming no change in currency exchange rates. For the year ending December 31, 2024, Cytek Biosciences expects to report positive net income.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 USD | +5.14% |
|
+1.96% | -37.17% |
06-12 | Cytek Biosciences to Seek M&A | CI |
06-12 | Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.17% | 752M | |
+6.37% | 216B | |
+10.21% | 189B | |
+28.22% | 153B | |
+34.42% | 114B | |
+0.80% | 63.2B | |
+19.21% | 54.78B | |
+0.13% | 48.47B | |
-4.16% | 38.88B | |
+2.39% | 36.14B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024